Abstract
Graft-mediated antileukemia (GVL) activity is a major factor contributing to the success of allogeneic hematopoietic stem transplantation (aHCT). Recent advances have permitted the establishment of GVL activity without the need for a myeloablative conditioning regimen, thereby permitting even older and sicker patients to avail of potentially curative therapy. Use of adoptive immunotherapy by combining reduced intensity conditioning and donor leukocyte infusion (DLI) has resulted in strategies that can be exploited to maximize GVL effects while minimizing toxicity. These advances, combined with new molecularly targeted agents, creates new possibilities to develop less toxic, curative therapy for a greater number of patients. This review summarizes pertinent information regarding the evidence in favor of GVL effects, the impact of disease type and mechanisms of GVL.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Porter D. L. and Antin, J. H. (1999) The graft-versus-leukemia effects of allogeneic cell therapy. [Review]. Annu. Rev. Med. 50, 369ā386.
Clift, R. A., Buckner, C. D., Appelbaum, F. R., et al. (1990) Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76, 1867ā1871.
Deeg, H. J., Storer, B., Slattery, J. T., et al. (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100, 1201ā1207.
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390ā3400.
Slavin, S., Nagler, A., Naparstek, E., et al. (1998) Nonmyeloablative stem cell transplantation rand cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91, 756ā763.
Giralt, S., Estey, E., Albitar, M., et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89, 4531ā4536.
Mielcarek, M., Martin, P. J., Leisenring, W., et al. (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Available online at First Edition Paper link, see Website: http://www.bloodjournal.org/. Blood 102(2), 756ā762.
Weiden, P. L., Storb, R., Tsoi, M. S., Graham, T. C., Lerner, K. G., and Thomas, E. D. (1976) Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J. Immunol. 116, 1212ā1219.
Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., and Thomas, E. D. (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl. J. Med. 304, 1529ā1533.
Weiden, P. L., Flournoy, N., Thomas, E. D., et al. (1979) Antileukemic effect of graftversus-host disease in human recipients of allogeneic-marrow grafts. New Engl. J. Med. 300, 1068ā1073.
Sullivan, K. M., Weiden, P. L., Storb, R., et al. (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73, 17201728.
Odom, L. F., August, C. S., Githens, J. H., et al. (1978) Remission of relapsed leukaemia during a graft-versus-host reaction. A "e;graft-versus-leukaemia reaction"e; in man? Lancet 2, 537ā540.
Collins, R. H., Jr., Rogers, Z. R., Bennett, M., Kumar, V., Nikein, A., and Fay, J. W. (1992) Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant. 10, 391ā395.
Higano, C. S., Brixey, M., Bryant, E. M., et al. (1990) Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 50, 175ā177.
Fefer, A., Sullivan, K. M., Weiden, P., et al. (1987) Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 244, 401ā408.
Gale, R. P., Horowitz, M. M., Ash, R. C., et al. (1994) Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 120, 646ā652.
Horowitz, M. M., Gale, R. P., Sondel, P. M., et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555ā562.
Apperley, J. F., Mauro, F. R., Goldman, J. M., et al. (1988) Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.[erratum; Br. J. Haematol. 70(2), 261]. Br. J. Haematol. 69, 239ā245.
Marmont, A. M., Horowitz, M. M., Gale, R. P., et al. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120ā2130.
Kolb, H. J., Mittermuller, J., Clemm, C., et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462ā2465.
Barnes, D. W. H., Corp, M. J., Loutit, J. F., and Neal, F. E. (1956) Treatment of murine leukaemia with X-rays and homologous bone marrow. Preliminary communication. Br. Med. J. 2, 626ā627.
Kolb, H. J., Schattenberg, A., Goldman, J. M., et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041ā2050.
Guglielmi, C., Arcese, W., Dazzi, F., et al. (2002) Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100, 397ā405.
Raiola, A. M., Van Lint, M. T., Valbonesi, M., et al. (2003) Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 31, 687ā693.
Shiobara, S., Nakao, S., Ueda, M., et al. (2001) Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation. Ther. Apheresis 5, 40ā45.
Collins, R. H., Jr., Shpilberg, O., Drobyski, W. R., et al. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433ā444.
Marks, D. I., Lush, R., Cavenagh, J., et al. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100, 3108ā3114.
de Lima, M., Bonamino, M., Vasconcelos, Z., et al. (2001) Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant. 27, 73ā78.
Porter, D. L., Collins, R. H., Jr., Hardy, C., et al. (2000) Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95, 1214ā1221.
Lokhorst, H. M., Schattenberg, A., Cornelissen, J. J., et al. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol. 18, 3031ā3037.
Dazzi, F., Szydlo, R. M., Craddock, C., et al. (2000) Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95, 67ā71.
Dazzi, F., Szydlo, R. M., Cross, N. C., et al. (2000) Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96, 2712ā2716.
Or, R., Shapira, M. Y., Resnick, I., et al. (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101, 441ā445.
Au, W. Y., Lie, A. K., Lee, C. K., Liang, R., and Kwong, Y. L.. (1999) Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 23, 1201ā1203.
Lee, J. H., Lee, K. H., Kim, S., et al. (2001) Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leukemia Res. 25, 305ā312.
Zikos, P., Van Lint, M. T., Lamparelli, T., et al. (1998) Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 83, 896ā903.
Appelbaum, F. R. (1997) Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). [Review] Leukemia 11(Suppl 4), S15ā17.
Passweg, J. R., Tiberghien, P., Cahn, J. Y., et al. (1998) Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 21, 153-158.
Collins, R. H., Jr., Goldstein, S., Giralt, S., et al. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26, 511ā516.
Zomas, A., Stefanoudaki, K., Fisfis, M., Papadaki, T., and Mehta, J.. (1998) Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramed-ullary relapse with plasmacytomas. Bone Marrow Transplant. 21, 1163ā1165.
Tricot, G, Vesole, DH, Jagannath, S, Hilton, J, Munshi, N, and Barlogie, B. (1996) Graft-versus-myeloma effect: proof of principle. Blood 87, 1196ā1198.
Alyea, E., Weller, E., Schlossman, R., et al. (2001) T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98, 934ā939.
Verdonck, L. F., Lokhorst, H. M., Dekker, A. W., Nieuwenhuis, H. K., and Petersen, E. J. (1996) Graft-versus-myeloma effect in two cases. Lancet 347, 800ā801.
Bertz, H., Burger, J. A., Kunzmann, R., Mertelsmann, R., and Finke, J. (1997) Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11, 281ā283.
Mehta, J., Powles, R., Singhal, S., Iveson, T., Treleaven, J., and Catovsky, D. (1996) Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant. 17, 371ā375.
Rondon, G., Giralt, S., Huh, Y., et al. (1996) Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 18, 669ā672.
Dreger, P. and Montserrat, E. (2002) Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. [Review]. Leukemia 16, 985ā992.
Sohn, S. K., Baek, J. H., Kim, D. H., et al. (2000) Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. [Review]. Am. J. Hematol. 65, 75ā80.
Khouri, I. F., Keating, M., Korbling, M., et al. (1998) Transplant-lite: induction of graftversus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16, 2817ā2824.
Khouri, I. F., Saliba, R. M., Giralt, S. A., et al. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98, 3595ā3599.
Branson, K., Chopra, R., Kottaridis, P. D., et al. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J. Clin. Oncol. 20, 4022ā4031.
Milpied, N., Fielding, A. K., Pearce, R. M., Ernst, P., and Goldstone, A. H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkinās disease. European Group for Blood and Bone Marrow Transplantation. J. Clin. Oncol. 14, 1291ā1296.
Akpek, G., Ambinder, R. F., Piantadosi, S., et al. (2001) Long-term results of blood and marrow transplantation for Hodgkinās lymphoma. J. Clin. Oncol. 19, 4314ā4321.
Carella, A. M., Cavaliere, M., Lerma, E., et al. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkinās disease and non-Hodgkinās lymphoma. J. Clin. Oncol. 18, 3918ā3924.
Porter, D. L., Stadtmauer, E. A., and Lazarus, H. M. (2003)ā GVHDā: graft-versus-host disease or graft-versus-Hodgkinās disease? an old acronym with new meaning. Bone Marrow Transplant. 31, 739ā746.
Eibl, B., Schwaighofer, H., Nachbaur, D., et al. (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88, 1501ā1508.
Childs, R., Chernoff, A., Contentin, N., et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl. J. Med. 343, 750ā758.
Rini, B. I., Zimmerman, T., Stadler, W. M., Gajewski, T. F., and Vogelzang, N. J. (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.[comment]. J. Clin. Oncol. 20, 2017ā2024.
Bregni, M., Dodero, A., Peccatori, J., et al. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99, 4234ā4236.
Bay, J. O., Fleury, J., Choufi, B., et al. (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 30, 95ā102.
Peccatori, J. Ciceri, F., Bernardi, M., et al. (2002) Evidence of allogeneic graft-versustumor effect in prostate and ovarian cancer. Haematologica 87(Suppl1), 12ā14.
Zetterquist, H., Hentschke, P., Thorne, A., et al. (2001) A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant. 28, 1161ā1166.
Moscardo, F., Martinez, J. A., Sanz, G. F., et al. (2000) Graft-versus-tumour effect in nonsmall-cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br. J. Haematol. 111, 708ā710.
Pedrazzoli, P., Da Prada, G. A., Giorgiani, G., et al. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94, 2409ā2415.
Morecki, S., Moshel, Y., Gelfend, Y., Pugatsch, T., and Slavin, S. (1997) Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int. J. Cancer 71, 59ā63.
Morecki, S., Yacovlev, E., Diab, A., and Slavin, S. (1998) Allogeneic cell therapy for a murine mammary carcinoma. Cancer Research. 58, 3891ā3895.
Childs, R. W., Bradstock, K. F., Gottlieb, D., Kefford, R., and Barrett, J. (2000) Nonmyeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: results of a pilot study. Blood 96(Part2), 353b..
Foster, A. E., Gottlieb, D. J., Marangolo, M., et al. (2003) Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy. J. Hematother. Stem Cell Res. 12, 93ā105.
Walter, E. A., Greenberg, P. D., Gilbert, M. J., et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl. J. Med. 333, 1038ā1044.
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., and Greenberg, P. D. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238ā241.
Gottschalk, S., Edwards, O. L., Sili, U., et al. (2003) Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBVassociated malignancies. Blood 101, 1905ā1912.
Hamel, Y., Blake, N., Gabrielsson, S., et al. (2002) Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum. Gene Ther. 13, 855ā866.
Regn, S., Raffegerst, S., Chen, X., Schendel, D., Kolb, H. J., and Roskrow, M.. (2001) Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 27, 53ā64.
Hromas, R., Cornetta, K., Srour, E., Blanke, C., and Broun, E. R. (1994) Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84, 1689ā1690.
Rooney, C. M., Smith, C. A., Ng, C. Y., et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549ā1555.
Emanuel, D. J., Lucas, K. G., Mallory, G. B., Jr., et al. (1997) Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 63, 1691ā1694.
Comoli, P., Labirio, M., Basso, S., et al. (2002) Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99, 2592ā2598.
Haque, T., Taylor, C., Wilkie, G. M., et al. (2001) Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72, 1399ā1402.
Restrepo, A., Albrecht, F., Raez, L. E., et al. (1999) Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. [Review] Crit. Rev. Oncogen. B, 239ā245.
Truitt, R. L., Johnson, B. D., McCabe, C., and Weiler, M. B. (1997) Graft versus leukemia. In: Graft-vs-Host Disease. Ferrara, J. L. M, Deeg, H. J., and Burakoff, S. J., eds. Marcel Dekker, New York, NY, p. 385.
Malkovska, V., Cigel, F., and Storer, B. E. (1994) Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumour immunity. Clin. Exp. Immunol. 96, 158ā165.
van Lochem, E., de Gast, B., and Goulmy, E. (1992) In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant. 10, 181ā183.
Sosman, J. A., Oettel, K. R., Smith, S. D., Hank, J. A., Fisch, P., and Sondel, P. M. (1990) Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLAD restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 75, 2005ā2016.
Kondo, Y., Shiobara, S., and Nakao, S. (2001) Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro. Exp. Hematol. 29, 471ā476.
Jiang, Y. Z., Kanfer, E. J., Macdonald, D., Cullis, J. O., Goldman, J. M., and Barrett, A. J. (1991) Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant. 8, 253ā258.
Korngold, R., and Sprent, J. (1987) T cell subsets and graft-versus-host disease. Transplantation 44, 335ā339.
Giralt, S., Hester, J., Huh, Y., et al. (1995) CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86, 4337ā4343.
Nimer, S. D., Giorgi, J., Gajewski, J. L., et al. (1994) Selective depletion of CD8+cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 57, 82ā87.
Alyea, E. P., Soiffer, R. J., Canning, C., et al. (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91, 3671ā3680.
Claret, E. J., Alyea, E. P., Orsini, E., et al. (1997) Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J. Clin. Invest. 100, 855ā866.
Faber, L. M., van Luxemburg-Heijs, S. A., Veenhof, W. F., Willemze, R., and Falkenburg, J. H. (1995) Generation of CD4+cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 86, 2821ā2828.
Jiang, Y. Z., and Barrett, A. J. (1995) Cellular and cytokine-mediated effects of CD4positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp. Hematol. 23, 1167ā1172.
Truitt, R. L., and Johnson, B. D. (1995) Principles of graft-vs.-leukemiareactivity. [Review] Biol. Blood Marrow Transplant. 1, 61ā68.
Palathumpat, V., Dejbakhsh-Jones, S., and Strober, S. (1995) The role of purified CD8+T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 60, 355ā361.
Barrett, A. J. (1997) Mechanisms of the graft-versus-leukemia reaction. [Review] Stem Cells 15, 248ā258.
Eisendle, K., Lang, A., Eibl, B., et al. (2003) Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br. J. Haematol. 120, 63ā73.
Eibl, B., Ebner, S., Duba, C., et al. (1997) Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 20, 215ā223.
Dietz, A. B., Litzow, M. R., Bulur, P. A., and Vuk-Pavlovic, S.(2001) Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T(H)1 T cells. Cytotherapy 3, 97ā105.
Trinchieri, G. (1989) Biology of natural killer cells. [Review] Adv. Immunol. 47, 187ā376.
Hercend, T., Takvorian, T., Nowill, A., et al. (1986) Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood 67, 722ā728.
Kruit, W. H., Goey, S. H., Lamers, C. H., et al. (1997) High-dose regimen of interleukin2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer. J. Immunother. 20, 312ā320.
Law, T. M., Motzer, R. J., Mazumdar, M., et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824ā832.
Okuno, K., Takagi, H., Nakamura, T., Nakamura, Y., Iwasa, Z., and Yasutomi, M. (1986) Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 58, 1001ā1006.
Kimura, H. and Yamaguchi, Y. (1995) Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 13, 31ā44.
Lim, S. H., Newland, A. C., Kelsey, S., et al. (1992) Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-a phase II study. Cancer Immunol. Immunother. 34, 337ā342.
Meropol, N. J., Barresi, G. M., Fehniger, T. A., Hitt, J., Franklin, M., and Caligiuri, M. A. (1998) Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46, 318ā326.
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., and Caligiuri, M. A. (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. [Review] Blood 100, 1935ā1947.
Ruggeri, L., Capanni, M., Casucci, M., et al. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94, 333ā339.
Zeis, M., Uharek, L., Glass, B., et al. (1997) Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br. J. Haematol. 96, 757ā761.
Glass, B., Uharek, L., Zeis, M., Loeffler, H., Mueller-Ruchholtz, W., and Gassmann, W. (1996) Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br. J. Haematol. 93, 412ā420.
Ruggeri, L., Capanni, M., Martelli, M. F., and Velardi, A. (2001) Cellular therapy: exploiting NK cell alloreactivity in transplantation. [Review] Curr. Opin. Hematol. 8, 355ā359.
Jiang, Y. Z., Barrett, A. J., Goldman, J. M., and Mavroudis, D. A. (1997) Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann. Hematol. 74, 1ā6.
Jiang, Y. Z., Cullis, J. O., Kanfer, E. J., Goldman, J. M., and Barrett, A. J. (1993) T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 11, 133ā138.
Aversa, F., Tabilio, A., Velardi, A., et al. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl. J. Med. 339, 1186ā1193.
Ruggeri, L., Capanni, M., Urbani, E., et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097ā2100.
Falkenburg, J. H., Marijt, W. A., Heemskerk, M. H., and Willemze, R. (2002) Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Curr. Opin. Hematol. 9, 497ā502.
Riddell, S. R., Murata, M., Bryant, S., and Warren, E. H. (2002) Minor histocompatibility antigens-targets of graft versus leukemia responses. Intl. J. Hematol. 2, 155ā161.
Goulmy, E. (1997) Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. [Review] Immun. Revs. 157, 125ā140.
Wang, W., Meadows, L. R., den Haan, J. M., et al. (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269, 1588ā1590.
Warren, E. H., Gavin, M. A., Simpson, E., et al. (2000) The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J. Immunol. 164, 2807ā2814.
Vogt, M. H., van den Muijsenberg, J. W., Goulmy, E., et al. (2002) The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 99, 3027ā3032.
Vogt, M. H., Goulmy, E., Kloosterboer, F. M., et al. (2000) UTY gene codes for an HLAB60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 96, 3126ā3132.
Vogt, M. H., de Paus, R. A., Voogt, P. J., Willemze, R., and Falkenburg, J. H. (2000) DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 95, 1100ā1105.
Brickner, A. G., Warren, E. H., Caldwell, J. A., et al. (2001) The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193, 195ā206.
Pierce, R. A., Field, E. D., Mutis, T., et al. (2001) The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167, 3223ā3230.
de Bueger, M., Bakker, A., Van Rood, J. J., Van der Woude, F., and Goulmy, E. (1992) Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocytedefined non-MHC antigens. J. Immunol. 149, 1788ā1794.
Warren, E. H., Gavin, M., Greenberg, P. D., and Riddell, S. R. (1998) Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. [Review] Curr. Opin. Hematol. 5, 429ā433.
Pardoll, D. M. (2002) Spinning molecular immunology into successful immunotherapy. [Review] Nat. Rev. Immunol. 2, 227ā238.
Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., and Witte, O. N. (1987) Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235, 85ā88.
Kurzrock, R., Blick, M. B., Talpaz, M., et al. (1986) Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. Ann. Intern. Med. 105, 673ā679.
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N., and Baltimore, D. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233, 212ā214.
Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., and Grosveld, G. (1985) Structural organization of the bcr gene and its role in the Phā translocation. Nature 315, 758761.
Fossum, B., Gedde-Dahl, T., 3rd, Breivik, J., et al. (1994) p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+and CD8+T cells recognize a peptide corresponding to a common mutation (13Gly-ā«Asp). Int. J. Cancer 56, 40ā45.
Yotnda, P., Garcia, F., Peuchmaur, M., et al. (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102, 455ā462.
Ohminami, H., Yasukawa, M., Kaneko, S., et al. (1999) Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 93, 925ā935.
Boer, J., Mahmoud, H., Raimondi, S., Grosveld, G., and Krance, R. (1997) Loss of the DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation. Leukemia 11, 299ā300.
Fornerod, M., Boer, J., van Baal, S., Morreau, H., and Grosveld, G. (1996) Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN. Oncogene 13, 1801ā1808.
von Lindern, M., Fornerod, M., Soekarman, N., et al. (1992) Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene. [Review] [74 refs]. Baillieres Clin. Haematol. 5, 857ā879.
de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675ā684.
Kakizuka, A., Miller, W. H., Jr., Umesono, K., et al. (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663ā674.
Molldrem, J. J., Lee, P. P., Wang, C., et al. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 10181023.
Molldrem, J. J., Clave, E., Jiang, Y. Z., et al. (1997) Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90, 2529ā2534.
Molldrem, J., Dermime, S., Parker, K., et al. (1996) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450ā2457.
Clave, E., Molldrem, J., Hensel, N., Raptis, A., and Barrett, A. J. (1999) Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. J. Immunother. 22, 1ā6.
Boon, T. and Old, L. J. (1997) Cancer tumor antigens. Curr. Opin. Immunol. 9, 681ā683.
Robbins, P. F. and Kawakami, Y. (1996) Human tumor antigens recognized by T cells. [Review] Curr. Opin. Immunol. 8, 628ā636.
Ohminami, H., Yasukawa, M., and Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286ā293.
Oka, Y., Elisseeva, O. A., Tsuboi, A., et al. (2000) Human cytotoxic T-lymphocyte responses specific forpeptides of the wild-type Wilmsā tumor gene (WT1) product. Immunogenetics 51, 99ā107.
Reddy, P., Teshima, T., Hildebrandt, G., et al. (2002) Interleukin 18 preserves aperforindependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood 100, 3429ā3431.
Brahmi, Z., Hommel-Berrey, G., Smith, F., and Thomson, B. (2001) NK cells recover early and mediate cytotoxicity via perforin/granzyme and Fas/FasL pathways in umbilical cord blood recipients. Hum. Immunol. 62, 782ā790.
Susskind, B., Shornick, M. D., Iannotti, M. R., et al. (1996) Cytolytic effector mechanisms of human CD4+cytotoxic T lymphocytes. Hum. Immunol. 45, 64ā75.
Kunitomi, A., Hori, T., Maeda, M., and Uchiyama, T. (2002) OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis. Intl. J. Hematol. 76, 260ā266.
Liu, J. H., Wei, S., Lamy, T., et al. (2002) Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 100, 1449ā1453.
Schmaltz, C., Alpdogan, O., Horndasch, K. J., et al. (2001) Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graftversus-leukemia effect. Blood 97, 2886ā2895.
Tanaka, Y., Takahashi, T., Nieda, M., et al. (2002) Generation of Fas-independent CD4+cytotoxic T-cell clone specific for p190 minor bcr-abl fusion peptide. Leukemia Res. 26, 317ā321.
Schmaltz, C., Alpdogan, O., Muriglan, S. J., et al. (2003) Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101, 2440ā2445.
Schmaltz, C., Alpdogan, O., Kappel, B. J., et al. (2002) T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8, 1433ā1437.
Middleton, P. G., Taylor, P. R., Jackson, G., Proctor, S. J., and Dickinson, A. M. (1998) Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92, 3943ā3948.
Nordlander, A., Uzunel, M., Mattsson, J., and Remberger, M. (2002) The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br. J. Haematol. 119, 1133ā1136.
Dickinson, A. M., Cavet, J., Cullup, H., Wang, X. N., Sviland, L., and Middleton, P. G. (2001) GvHD risk assessment in hematopoietic stem cell transplantation: role of cytokine gene polymorphisms and an in vitro human skin explant model. Hum. Immunol. 62, 1266ā1276.
Cavet, J., Dickinson, A. M., Norden, J., Taylor, P. R., Jackson, G. H., and Middleton, P. G. (2001) Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 98, 1594ā1600.
Warle, M. C., Farhan, A., Metselaar, H. J., et al. (2002) Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transplant. 8, 603ā611.
Mazariegos, G. V., Reyes, J., Webber, S. A., et al. (2002) Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation 73, 1342ā1345.
Awad, M. R., Webber, S., Boyle, G., et al. (2001) The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J. Heart Lung Transplant. 20, 625ā630.
Poole, K. L., Gibbs, P. J., Evans, P. R., Sadek, S. A., and Howell, W. M. (2001) Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transplant Immunol. 8, 259ā265.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Hogan, W.J., Deeg, H.J. (2005). Stem Cell Transplantation: Graft-Mediated Antileukemia Effects. In: Ludewig, B., Hoffmann, M.W. (eds) Adoptive Immunotherapy: Methods and Protocols. Methods in Molecular Medicineā¢, vol 109. Humana Press. https://doi.org/10.1385/1-59259-862-5:421
Download citation
DOI: https://doi.org/10.1385/1-59259-862-5:421
Publisher Name: Humana Press
Print ISBN: 978-1-58829-406-7
Online ISBN: 978-1-59259-862-5
eBook Packages: Springer Protocols